These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 6224623)

  • 21. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
    Petrova G; Strateva T; Miteva D; Lazova S; Perenovska P
    J Infect Dev Ctries; 2016 Nov; 10(11):1265-1267. PubMed ID: 27886041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of
    Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
    Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dosage tobramycin treatment of children with cystic fibrosis. Bacteriological effect and clinical ototoxicity.
    Thomsen J; Friis B
    Int J Pediatr Otorhinolaryngol; 1979 Jul; 1(1):33-40. PubMed ID: 553884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Barclay ML; Begg EJ; Chambers ST; Thornley PE; Pattemore PK; Grimwood K
    J Antimicrob Chemother; 1996 Jun; 37(6):1155-64. PubMed ID: 8836818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    J Antimicrob Chemother; 1985 May; 15(5):545-9. PubMed ID: 3924879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxalactam therapy for bacterial infections.
    Winston DJ; Busuttil RW; Kurtz TO; Young LS
    Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term tobramycin aerosol therapy in cystic fibrosis.
    Steinkamp G; Tümmler B; Gappa M; Albus A; Potel J; Döring G; von der Hardt H
    Pediatr Pulmonol; 1989; 6(2):91-8. PubMed ID: 2494640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of aerosolized antibiotics in cystic fibrosis patients.
    Moss RB
    Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microbiological and immunologic considerations with aerosolized drug delivery.
    LiPuma JJ
    Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial.
    Puvvadi R; Mikkelsen H; McCahon L; Grogan S; Ditcham W; Reid DW; Lamont I; Stick SM; Clements B
    J Cyst Fibros; 2021 Mar; 20(2):316-323. PubMed ID: 33341406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftazidime - a significant advance in the treatment of cystic fibrosis.
    David TJ; Phillips BM; Connor PJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():337-40. PubMed ID: 6352639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 39. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
    Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
    Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
    Stelmach I; Korzeniewska A; Stelmach W
    Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.